BSECompany Update3 Nov 2026 · 3 Nov 2026, 02:01 pm
Newspaper Publication of Unaudited Financial Results for the quarter and half year ended 30th September 2026
Chemcrux Enterprises Ltd · 540395
✦ AI SummaryResults
Chemcrux Enterprises Ltd and Akums Drugs and Pharmaceuticals Ltd have published unaudited financial results for the quarter and half year ended September 30, 2026, with details available on their respective websites and BSE.
Analysis Scores
Earnings Impact5/10
Growth Catalyst3/10
Governance Concern2/10
Regulatory Risk1/10
Balance Sheet Risk4/10
Liquidity Impact6/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Chemcrux Enterprises Ltd - 540395 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Attachments (1)
📄pdf
Download →
36569274-b0b2-431d-8227-b16d393e444c.pdf
View document text
03rd November 2026
BSE LIMITED
Phiroze Jeejeebhoy Towers
Department of Corporate Services
Dalal Street, Mumbai- 400 001
Dear Sir/Madam
Subject: Newspaper Publication of Standalone & Consolidated Unaudited Financial
Results for the quarter and half year ended 30th September 2026
Ref: BSE Scrip ID: CHEMCRUX BSE Scrip Code: 540395
Pursuant to Regulation 30 & 47 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015, please find enclosed newspaper publication of
Standalone & Consolidated Unaudited Financial Results of the Company for the quarter
and half year ended 30th September 2026 published in Financial Express (English &
Gujarati Edition) today i.e., 03rd November 2026.
Kindly take the above on your record.
Yours faithfully
For CHEMCRUX ENTERPRISES LIMITED
Dipika Rajpal
Company Secretary & Compliance Officer
Enclosed: As above
HEC INFRA PROJECTS LIMITED
RegisteredOffice:Sigma-1Corporates,CorporateHouseNo.6,SindhuBhavanRoad,
Nr.MaanPartyPlotCrossRoad,Bodakdev,Ahmedabad-380054,Gujarat.
Phone:+91-79-40086771-74,E:elect@hecproject.com,W:www.hecprojects.in,
CIN:L45200GJ2005PLC046870
UNAUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS
FOR THE QUARTER ENDED ON 30TH SEPTEMBER, 2026
TheBoardofDirectorsintheirmeetingheldon2ndNovember2026,haveapproved
andtakenonrecordtheUnauditedFinancialResultsforthequarterendedon30th
September,2026intermsofRegulation33oftheSEBI(LODR)Regulations,2015.
The aforesaid Unaudited Financial Results for the quarter ended 30th September,
2026 along with Limited Review Report thereon are available on website of NSE
Limited at www.nseindia.com and also on Company website and can also be
accessedbyscanningbelowQuickResponseCode:
ForandonbehalfoftheBoardofDirectorsof
HECInfraProjectsLimited
SD/-
Place:Ahmedabad GaurangShah-(ManagingDirector)
Date :2ndNovember2026 DIN:01756079
DEVYANI INTERNATIONAL LIMITED
CorporateIdentificationNumber:L15135HR1991PLC143853
Registered&CorporateOffice: Plot No. 18, Sector – 35,
Gurugram – 122004, Haryana Tel: +91-124-4566300,
E-mail: companysecretary@dil-rjcorp.com, Website: www.dil-rjcorp.com
Statement of Standalone and Consolidated financial results for the Quarter and Half
Year ended 30 September 2026
[Regulation 33 read with Regulation 47 (1) (b) of the SEBI (LODR) Regulations, 2015]
The Board of Directors of the Company at its meeting held on 2 November
2026 inter-alia considered and approved the Unaudited Financial Results of
the Company (Standalone and Consolidated) for the Quarter and Half Year
ended 30 September 2026. (‘Financial Results’)
The Financial Results along with the Limited Review Reports, have been
disseminated on the Company’s website at https://dil-rjcorp.com/wp-
content/uploads/2026/11/financial-results.pdf and can be accessed by
scanning the QR Code.
ForandonbehalfofBoardofDirectorsof
DevyaniInternationalLimited
Sd/-
ManishDawar
Place :Gurugram Whole-timeDirector(President&GroupCEO)
Dated:2November2026 DIN:00319476
fu{¢ûk yuLxh«kRÍeÍ r÷r{xuz
((‚‚ee yykkEE yyuu™™:: yyuu÷÷0011111100SSssuu11999966……eeyyuu÷÷‚‚ee002299332299))
hrs. ykurV‚: 330, rxÙrðÞk fkuBÃ÷uõ‚, ™xw¼kR ‚fo÷, hu‚fku‚o, ðzkuËhk - 390007
R-{u÷: girishshah@chemcrux.com Vku™: 0265-2984803/2988903 ðuƒ‚kRx: www.chemcrux.com
TUESDAY, NOVEMBER 3, 2026 WWW.FINANCIALEXPRESS.COM
FINANCIAL EXPRESS
Fusion Finance Limited
3¢ Fusi
& AKUMS DRUGS AND PHARMACEUTICALS LIMITED
= FUSION
Ao Finance CIN: LES100DL1994PLCOG1287
CIN: L24239DL2004PLC125888
Registered address: H-1, C Block, Community Centre, Naraina Vihar, New Delhi - 110028
Regd. Office: 304, 3° Floor, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (India) Corporate office: Plot no. 86, Institutional Sector 32, Gurugram, Haryana - 122001
Akums Corporate Office: Akums House, Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, Delhi-110083 Contact Person: Vikrant Sadana, Company Secretary and Compliance Officer; Tal.: +81-124-6910500
Phone: +91-11-69041000, Fax: +91-11-27023256, E-mail: akumsho@akums.net, Website: www.akums.in E-mail: companysecretary@fusionfin.com; Website: www.fusionfin.com
Extract of Unaudited Financial results for the quarter and half year ended September 30, 2026
UNAUDITED (STANDALONE & CONSOLIDATED) FINANCIAL RESULTS (¥ in crore unless otherwise stated)
| Quarter ended | Half year ended Year ended
FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026
5. | Pasticulars September | June 30, September | September September | March 31,
No. | | 30,2026 | 2026 | 30,2025 | 30,2026 | 30,2025 | 2026
The Board of Directors of Akums Drugs and Pharmaceuticals Limited (“the Company™), | | Unaudited| Unaudited| Unaudited| Unaudited| Unaudited Audited
For more information,
on recommendation of the audit committee, at its meeting held on November 2, 2026, 3 “T.m.a_lulnc_:omr_-:.frnm t_jpelratio.nls dassi | 4581? | a1579 leB.?E!“ 8580? 1,698'53
please scan:
approved the Unaudited (Standalone & Consolidated) Financial Results for the Quarter and
2 |Met Profit/(loss) for the period (before Tax, |
half year ended September 30, 2026. | Exceptional and/or Extraordinary items) | 86.48 | 62,41 | (22.14) | 148.89 | 1114.39) | (62.93)
The full Financial Results along with the Limited Review Report are available on the websites 3 | Met Profit/ (floss) for the period before tax (after
] Exceptional and/or Extraordinary items) | 86.48 | 62.41 | (22.14) | 146.8% | (114.39) | i52.933_
of the stock exchanges at www.bseindia.com and www.nseindia.com, and also posted on the
website of the Company and can be accessed at www.akums.in/investors/financial-report/. 4 | Net Profit/(loss) for the period after tax (after
| Exceptional and/or Extraordinary items) | 86.48 | 62.41 | (22.14) | 148.89 | (114.39) | 13.85 |
For Akums Drugs and Pharmaceuticals Limited
5 | Total Comprehensive Income for the period
Sd/- [Compri sing Profit/(loss) for the period (after tax)
__and Other Comprehensive Income (after tax)] | 88,26 | 59.61__ {29.300 | 147,87 | (11913) | 1].60__
Sanjeev Jain
5 Paid up Equity Share Capital
Date: November 2, 2026 Managing Director
| | (face value of ¥ 10/- each) | 161.59 | 161.56 13118 | 161.58 | 13118 | 161.52 |
Place: Delhi DIN: 00323433
7. [Resarvasiexciuding Revalltian Reserve) | 7208 (1939)| (22194)| 7208| (22184)| (8363)
8 | Securities Premium Account 2,38018 | 237852 | 200898 238018 200898 237804
L) | Met worth 261385 | 2,520.68 | 1,818.22 | 2.613.85 | 1,818.22 | 2,455,083
10 | Paid up Debt Capital / Outstanding Debt 593633 | 584034| 493362 593633| 4,93362| 557076
TBO Tek Limited
11 | Qutstanding Redeemable Preference Shares - =] = -
tbo.com
12 | Debt Equity Ratio 2.27 232 257 2.27 2.57 2.27
CIN: L74999DL2006PLC155233
Regd. Office: Unit No. 501, 5" Floor, Worldmark-4, Asset Area No. LP-IB-04, Gateway District, Aerocity, Earnings Per Share (face value of ¥ 10/- each)
Near Indira Gandhi International Airport, New Delhi-110037 B | (not annualised for quarter and half-year endec‘]_ | | | | | | |
Corporate Office: Plot No. 728, Udyog Vihar Phase-V Gurugram-122016, Haryana, India
[%. Raslc . | 256 | {1.69) | 9.22| l8en| 10
Tel. No.: +91124 499 8999, Email: corporatesecretarial@tbo.com, Website: www.tbo.com
| | 2. Diluted: | 5.32 | 3.85 | {1.69) | 217 | {8.97) | 1M |
STATEMENT OF UNAUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS
14 | Total debts to tolal assets | 0.67 | 087 | 0.70 | 0.67 | 070 067
FOR THE QUARTER AND HALF YEAR ENDED ON SEPTEMBER 30, 2026
15 | Net profit/{loss) margin (%) 17.81% 13.62% (5.12%) 1577% | (13.02%) | 0.80%
16 | Capital Redemption Reserve 7 IS 7 IS 7 AN 7 IR 7 7N
The Board of Directors of the Company, at their meeting held on November 02, 2026, approved
the Unaudited Standalone & Consolidated Financial Results (“Financial Results”) of the Company For more 1?_j Debentura Redemption Reserve | MA | NA_E MNA | NA_ A | NA__
information
for the Quarter and Half Year ended September 30, 2026. 1| Dabt Service Govarage Hallo, . A | N NA | A | DA | NA|
please scan:
The Financial Results along with the Limited
[Showing first 8,000 characters — download PDF for full document]